Prediction of Visual Field Progression from OCT Structural Measures in Moderate to Advanced Glaucoma.
Adult
Aged
Area Under Curve
Disease Progression
Female
Follow-Up Studies
Glaucoma, Open-Angle
/ diagnosis
Humans
Intraocular Pressure
/ physiology
Machine Learning
Male
Middle Aged
Nerve Fibers
/ pathology
Prospective Studies
Retinal Ganglion Cells
/ pathology
Tomography, Optical Coherence
Vision Disorders
/ diagnosis
Visual Acuity
/ physiology
Visual Fields
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
27
09
2020
revised:
23
01
2021
accepted:
25
01
2021
pubmed:
3
2
2021
medline:
11
9
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
To test the hypothesis that visual field (VF) progression can be predicted from baseline and longitudinal optical coherence tomography (OCT) structural measurements. Prospective cohort study. A total of 104 eyes (104 patients) with ≥3 years of follow-up and ≥5 VF examinations were enrolled. We defined VF progression based on pointwise linear regression on 24-2 VF (≥3 locations with slope less than or equal to -1.0 dB/year and P < .01). We used elastic net logistic regression (ENR) and machine learning to predict VF progression with demographics, baseline circumpapillary retinal nerve fiber layer (RNFL), macular ganglion cell/inner plexiform layer (GCIPL) thickness, and RNFL and GCIPL change rates at central 24 superpixels and 3 eccentricities, 3.4°, 5.5°, and 6.8°, from fovea and hemimaculas. Areas-under-ROC curves (AUC) were used to compare models. Average ± SD follow-up and VF examinations were 4.5 ± 0.9 years and 8.7 ± 1.6, respectively. VF progression was detected in 23 eyes (22%). ENR selected rates of change of superotemporal RNFL sector and GCIPL change rates in 5 central superpixels and at 3.4° and 5.6° eccentricities as the best predictor subset (AUC = 0.79 ± 0.12). Best machine learning predictors consisted of baseline superior hemimacular GCIPL thickness and GCIPL change rates at 3.4° eccentricity and 3 central superpixels (AUC = 0.81 ± 0.10). Models using GCIPL-only structural variables performed better than RNFL-only models. VF progression can be predicted with clinically relevant accuracy from baseline and longitudinal structural data. Further refinement of proposed models would assist clinicians with timely prediction of functional glaucoma progression and clinical decision making.
Identifiants
pubmed: 33529590
pii: S0002-9394(21)00044-1
doi: 10.1016/j.ajo.2021.01.023
pmc: PMC8580576
mid: NIHMS1690784
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-181Subventions
Organisme : NEI NIH HHS
ID : R01 EY029792
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY030142
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY031725
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Ophthalmic Surg Lasers Imaging. 2012 Sep-Oct;43(5):416-24
pubmed: 22658308
Am J Ophthalmol. 2017 Mar;175:37-44
pubmed: 27914978
IEEE Trans Biomed Eng. 2014 Apr;61(4):1143-54
pubmed: 24658239
J Glaucoma. 2017 Apr;26(4):373-382
pubmed: 28118204
Bioinformatics. 2017 Jul 15;33(14):i359-i368
pubmed: 28881998
Arch Ophthalmol. 2005 Feb;123(2):193-9
pubmed: 15710815
Proc SPIE Int Soc Opt Eng. 2014 Mar 21;2014:
pubmed: 25593676
Ophthalmology. 2014 Mar;121(3):741-9
pubmed: 24290806
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2334-9
pubmed: 25698708
Invest Ophthalmol Vis Sci. 2014 Apr 07;55(4):2228-36
pubmed: 24458154
Am J Ophthalmol. 2019 Dec;208:19-29
pubmed: 31247169
IEEE Trans Biomed Eng. 2014 Jul;61(7):2112-24
pubmed: 24710816
Br J Ophthalmol. 2014 Sep;98(9):1230-5
pubmed: 24795333
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4346-51
pubmed: 15557442
Prog Retin Eye Res. 2017 Jan;56:107-147
pubmed: 27773767
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):612-24
pubmed: 24408977
Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2382-9
pubmed: 22427577
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4815-23
pubmed: 27623336
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4600-6
pubmed: 16303955
Ophthalmology. 2019 Jun;126(6):822-828
pubmed: 30731101
Arch Ophthalmol. 2003 Jan;121(1):48-56
pubmed: 12523884
Transl Vis Sci Technol. 2020 Jun 30;9(7):50
pubmed: 32832255
Ophthalmology. 2007 Jan;114(1):10-9
pubmed: 17095090
Am J Ophthalmol. 2019 Nov;207:268-278
pubmed: 31238025
Invest Ophthalmol Vis Sci. 2014 Oct 23;55(12):7814-20
pubmed: 25342615
Arch Ophthalmol. 2011 Sep;129(9):1205-11
pubmed: 21911669
BMC Ophthalmol. 2011 Aug 04;11:20
pubmed: 21816080
PLoS One. 2014 Jan 30;9(1):e85941
pubmed: 24497932
Ophthalmology. 2020 Jul;127(7):888-900
pubmed: 32173112
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT511-8
pubmed: 27454660
Invest Ophthalmol Vis Sci. 2012 May 14;53(6):2702-7
pubmed: 22447872
Ophthalmology. 2012 Feb;119(2):308-13
pubmed: 22182800
Am J Ophthalmol. 2018 Sep;193:71-79
pubmed: 29920226
Ophthalmology. 2004 Sep;111(9):1627-35
pubmed: 15350314
Arch Ophthalmol. 1993 May;111(5):651-6
pubmed: 8489448
Transl Vis Sci Technol. 2019 Sep 11;8(5):2
pubmed: 31555493
J Glaucoma. 2010 Mar;19(3):167-75
pubmed: 19528827
Am J Ophthalmol. 2002 Aug;134(2):177-85
pubmed: 12140023
Invest Ophthalmol Vis Sci. 2013 Sep 19;54(9):6234-41
pubmed: 23908183
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):945-53
pubmed: 18326717
Arch Ophthalmol. 2006 Jun;124(6):853-9
pubmed: 16769839